Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2014-05-09 Director's Dealing
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2014-05-09 English
PRIMARY DOCUMENT
Director's Dealing
2014-05-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 5, 2014, reporting the submission of matters to a vote of security holders at the company's 2014 Annual Meeting. It details the voting results for the election of directors and ratification of auditors. There are no financial statements or substantive financial data included, and the document primarily reports voting outcomes from the Annual Meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3474 characters, which is consistent with a voting results announcement rather than a full report or presentation.
2014-05-08 English
Regulatory Filings 2014
Regulatory Filings
2014-04-28 English
Regulatory Filings 2014
Regulatory Filings
2014-04-22 English
POS AM
Capital/Financing Update Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to Form S-1 Registration Statement filed with the SEC by Atossa Genetics Inc. It references the Securities Act of 1933 and SEC registration numbers, and it is related to the registration of shares for resale by a selling stockholder. The document includes a preliminary prospectus for the sale of common stock and discusses the registration process, selling stockholder details, and related legal and financial information. This type of filing is a capital raising and securities registration document, which fits the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or other financial report, but rather a registration statement amendment related to capital raising activities.
2014-04-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.